Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases and Renal Cell Carcinoma, Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H.

Trial Profile

Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases and Renal Cell Carcinoma, Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; Fludarabine
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Fanconi's anaemia; Graft-versus-host disease; Haematological malignancies; Hairy cell leukaemia; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Plasma cell leukaemia; Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HIMSUM
  • Most Recent Events

    • 08 Mar 2013 Planned number of patients changed from 20 to 45 as reported by ClinicalTrials.gov.
    • 12 Apr 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 22 Dec 2010 Planned End Date changed to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top